Spleen: Splenectomy Splenectomy Vaccination VaccinationsHemophilus influenzae Type BHiB Single DoseMeningococcusQuadrivalent Conjugate ACWY – 2 Doses ≥ 8 Weeks ApartMonovalent Serogroup B Series – 2 Doses ≥ 4 Weeks ApartPneumococcus13-Valent Conjugate (PCV13) – 1 Dose Initially23-Valent Polysaccharide (PPSV23) – 1 Dose After 8 WeeksTimingElective: Finish 2 Weeks Before – Start 10-12 Weeks PriorEmergent: Start 2 Weeks After (Impaired Functional Ab Responses Prior)Give Just Prior to Discharge if Concern for Loss to Follow UpBoosters Mn HiB: NoneMCV: Every 5 Years (Quadrivalent Conjugate)PCV: After 5 Years & At Age 65 (PPSV23)Some Recommend Every 5-7 Years Splenectomy BasicsPreserved Function Requires: 1/3 of Splenic MassIndications:Trauma (Most Common Cause)ITP (Most Common Elective Cause)Hereditary SpherocytosisFelty SyndromeSplenic AbscessSplenic Cyst (Hydatid Cysts)Splenic Vein ThrombosisCancerApproach ComparisonLaparoscopicLower Morbidity & MortalityShorter Hospital Stay & Faster RecoveryHigher OR Cost but Lower Total Cost from Decreased StayOpenHigh Risk for Injury to PancreasElective SplenectomyApproach: LaparoscopicLaparoscopic Approaches:Lateral (Right-Lateral Decubitus)Most Common ApproachAnteriorIndications:Massive Splenomegaly (> 23 cm of 3 kg)If Another Procedure is RequiredMay Require an Accessory Extraction Incision if Too LargePosteriorMore Difficult Due to Thick Muscle MassProcedure:Mobilize LigamentsDivide Splenocolic LigamentDivide Gastrosplenic Ligament & Short GastricsLigate Close to Spleen (Avoid Gastric Injury)Divide Splenorenal Ligament & Visualize Splenic VesselsResect SpleenDivide Splenic Artery & VeinAvoid Injury to Tail of PancreasDivide Splenophrenic Ligament (Last)Maintains Cephalad/Lateral RetractionSpleen Morcellated & ExtractedLigate Hilar Vessels Before Splenophrenic DivisionTraumatic SplenectomyApproach: OpenProcedure:Mobilize Spleen & Pancreatic Tail to Midline TogetherLeft Hand Around Spleen & Retract MediallyDivide Splenophrenic LigamentFully MobilizeDivide Gastrosplenic Ligament & Short GastricsLigate Close to Spleen (Avoid Gastric Injury)Divide Splenocolic LigamentLigate Splenic Artery & Then Splenic VeinAvoid Injury to Tail of PancreasLigate Hilar Vessels After Complete Mobilization Post-Splenectomy Hematologic Changes Laboratory ChangesLeukocytosis (WBC)Reliable Markers for Infection After Traumatic Splenectomy:WBC > 15,000 on Postoperative Day #5Platelet/WBC < 20 on Postoperative Day #5Generally Transient Although Lymphocytosis & Monocytosis are More PersistentPolycythemia (RBC)Thrombocytosis (Plt) – Generally TransientPeripheral Blood Smear ChangesHowell-Jolly Bodies (Nuclear Fragments)Poikilocytosis (Abnormally Shaped RBC)Target Cells (Codocyte)Spur Cells (Acanthocytes)Pappenheimer Bodies (Fe Deposits) Howell-Jolly Bodies 1 Poikilocytosis 2 Pappenheimer Bodies 3 Post-Splenectomy Complications Postoperative HemorrhageMost Common Early ComplicationFrom Short Gastrics (#1 Most Common) or Splenic VesselsOverwhelming Post-Splenectomy Infection (OPSI)/Post-Splenectomy Sepsis Syndrome (PSSS)Infection Showing Rapid Progression to Sepsis in Post-Splenectomy PatientsHigh MortalityCause: Loss of IgM Mediated Immunity to Capsulated Bacteria (HiB, PC & MC)Most Common Organism: PneumococcusMost Common Infections: PNA, Primary Bacteremia & MeningitisRisk Factors:Peds (Especially Age < 5)If Splenectomy Due to:MalignancyHemolytic Disorder (Thalassemia Major #1, Sickle Cell #2, Hereditary Spherocytosis, ITP)Tx: Vancomycin & CeftriaxoneAntibiotic ProphylaxisPossible Indications:First Year Post-SplenectomyAge < 5 YearsImmunocompromisedHistory of Sepsis from Encapsulated OrganismsRegimen: Penicillin or AmoxicillinIf Penicillin Allergy: CephalosporinOther ComplicationsPancreatic LeakPancreatic Tail Contained in the Splenorenal LigamentMay See Postop Fluid Collection in the Lesser SacSplenosis*See Spleen: SplenosisVenous ThromboembolismIncluding Portal/Splenic Vein Thrombosis Mnemonics Vaccine Booster Frequency After SplenectomyH-“IB” – Initial BolusOnly Need One Initial DoseM-“CV” & P-“CV” – Continued V (5)Require Continued Doses After Five Years References Mourao PHO, Haggstrom M. Wikimedia Commons. (License: CC BY-SA-3.0)Uthman E, Bhimji S, Haggstrom M. Wikimedia Commons. (License: CC BY-4.0)Mourao PHO. Wikimedia Commons. (License: CC BY-SA-4.0)